Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30101
Immunohistochemical Expression of β-catenin and Epidermal Growth Factor Receptor in Adamantinomatous Craniopharyngioma

Authors: Ghada Esheba, Fatimah Alturkistani, Arwa Obaid, Ahdab Bashehab, Moayad Alturkistani

Abstract:

Introduction: Craniopharyngiomas (CPs) are rare epithelial tumors located mainly in the sellar/parasellar region. CPs have been classified histopathologically, genetically, clinically and prognostically into two distinctive subtypes: adamantinomatous and papillary variants. Aim: To examine the pattern of expression of both the β-catenin and epidermal growth factor receptor (EGFR) in surgically resected samples of adamantinomatous CP, and to asses for the possibility of using anti-EGFR in the management of ACP patients. Materials and methods: β-catenin and EGFR immunostaining was performed on paraffin-embedded tissue sections of 18 ACP cases. Result: 17 out of 18 cases (94%) of ACP exhibited strong nuclear/cytoplasmic expression of β-catenin, 15 (83%) of APC cases were positive for EGFR. Conclusion: Nuclear accumulation of β-catenin is a diagnostic hallmark of ACP. EGFR positivity in most cases of ACP could qualify the use of anti-EGFR therapy. 

Keywords: Craniopharyngioma, adamantinomatous, papillary, epidermal growth factor receptor, B-catenin.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1124577

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1396

References:


[1] S.T. Qi, J. Zhou, J. Pan, C. Zhang, C. Silky, X.R. Yan Epithelial– mesenchymal transition and clinicopathological correlation in craniopharyngioma Histopathology, 61 (4) (2012), pp. 711–725.
[2] J.P. Martinez-Barbera. Biology of human craniopharyngioma: lessons from mouse models. J Endocrinol (2015)
[3] S. Puget, M. Garnett, A. Wray, J. Grill, J.L. Habrand, N. Bodaert, M. Zerah, M. Bezerra, D. Renier, A. Pierre-Kahn, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg, 106 (1 Suppl.) (2007), pp. 3–12
[4] Grover WD, Rorke LB. Invasive craniopharyngioma. Journal of neurology, neurosurgery, and psychiatry. 1968;31(6):580-2.
[5] Van Effenterre R, Boch AL. Craniopharyngioma in adults and children: a study of 122 surgical cases. Journal of neurosurgery. 2002;97(1):3-11.
[6] Larkin, S. J., & Ansorge, O. (2012). Pathology and pathogenesis of craniopharyngiomas. Pituitary, 16(1), 9-17.
[7] Prabhu, V. C., & Brown, H. G. (2005). The pathogenesis of craniopharyngiomas. Child's Nervous System, 21(8), 622-627.
[8] Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery. 1994;35(6):1001-10; discussion 10-1.
[9] Duff J, Meyer FB, Ilstrup DM, Laws ER, Jr., Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000;46(2):291-302; discussion -5.
[10] Gabriel Zada, Ning Lin, Eric Ojerholm, Shakti Ramkissoon, & Edward R. Laws. (2010). Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships. Neurosurgical Focus, 28(4), E4.
[11] Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and biophysical research communications. 2004;319(1):1-11.
[12] Herbst RS. Review of epidermal growth factor receptor biology. International journal of radiation oncology, biology, physics. 2004;59(2 Suppl):21-6.
[13] Yu WH, Woessner JF, Jr., McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes & development. 2002;16(3):307-23.
[14] Lee CH, Hung HW, Hung PH, Shieh YS. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Molecular cancer. 2010;9:64.
[15] Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO reports. 2003;4(2):166-71.
[16] Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer cell. 2003;4(6):499-515.
[17] Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)- Wnt-1 and MMTV-c-Neu transgenic carcinomas. The Journal of biological chemistry. 2002;277(25):22692-8.
[18] D. Atkins, K.A. Reiffen, C.L. Tegtmeier, H. Winther, M.S. Bonato, S. Storkel. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem, 52 (7) (2004), pp. 893–901
[19] Keisuke Kato. "Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma", The Journal of Pathology, 07/2004
[20] Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, et al. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta neuropathologica. 2005;109(6):589-97.
[21] Annett Hölsken, Department of Neuropathology, University Hospital Erlangen, Schwabachanlage. EGFR Signaling Regulates Tumor Cell Migration in Craniopharyngiomas.